TGFB1 and prostate carcinoma: Weimin et al., have also reported that equipment of CAR T cells with chimeric cytokine switch receptor TGFβ/IL-7 not only could enhance their cytotoxic activity, cytokine production ability (e.g. IFNγ and TNFα) and proliferation capacity but also could reduce the expression of inhibitory receptors (e.g. PD-1 and LAG-3) in a prostate cancer model (30).